Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Depreciation and Depletion: 2015-2025

Historic Depreciation and Depletion for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to $600,000.

  • Cartesian Therapeutics' Depreciation and Depletion rose 100.00% to $600,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 155.56%. This contributed to the annual value of $1.2 million for FY2024, which is 71.43% up from last year.
  • As of Q3 2025, Cartesian Therapeutics' Depreciation and Depletion stood at $600,000, which was down 0.00% from $600,000 recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Depreciation and Depletion registered a high of $600,000 during Q1 2025, and its lowest value of $100,000 during Q1 2021.
  • For the 3-year period, Cartesian Therapeutics' Depreciation and Depletion averaged around $336,364, with its median value being $200,000 (2024).
  • Per our database at Business Quant, Cartesian Therapeutics' Depreciation and Depletion crashed by 50.00% in 2021 and then surged by 200.00% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' Depreciation and Depletion (Quarterly) stood at $200,000 in 2021, then remained steady at $200,000 in 2022, then remained steady at $200,000 in 2023, then soared by 150.00% to $500,000 in 2024, then skyrocketed by 100.00% to $600,000 in 2025.
  • Its last three reported values are $600,000 in Q3 2025, $600,000 for Q2 2025, and $600,000 during Q1 2025.